CD274 and non-small cell lung carcinoma: Guo-Wu Zhou et al. [18] conducted a similar meta-analysis comparing anti-PD1/PD-L1 antibody therapy with chemotherapy for pretreated NSCLC patients, but they only included three randomized clinical trials enrolling 1141 patients who received treatment with nivolumab or atezolizumab.